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Abstract

Stoichiochemistry

Phenibut ( -phenyl--aminobutyric acid) is a
psychoactive GABA analogue marketed as a
nutritional supplement and “nootropic” online.
Phenibut consumption poses a high risk of
potential abuse. Withdrawal from Phenibut mimics
benzodiazepine and alcohol withdrawal. Without
proper management, Phenibut withdrawal may be
equally as dangerous as benzodiazepine and
alcohol withdrawal. Baclofen can be prescribed for
outpatient symptomatic relief of Phenibut
withdrawal.
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Phenibut ( -phenyl--aminobutyric acid) is a psychoactive GABA analogue gaining
popularity in the United States as a nootropic dietary supplement. Phenibut primarily acts on
GABA-B, resulting in anxiolytic effects and depression: decreased levels of consciousness,
muscle tone, respiratory drive, thermoregulation and altered hemodynamics.
Phenibut also has stimulatory activity on dopamine receptors and antagonizing activity on phenethylamine (PEA). Although, Phenibut is often advertised to users for its nootropic
properties, including facilitated memory-enhancement (at 5-10mg/kg), a significant amount
of Phenibut users self-admittingly use at higher doses to achieve anxiolytic and tranquilizing
effects (50-100mg/kg). The combination of accessibility and marketing of Phenibut as a
“nutritional supplementation” has made Phenibut a significant drug-of-potential abuse in
American society. Therefore, it is important that American physicians understand the
standard-of-care management for Phenibut withdrawal.
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Case
33 y/o M presented to the emergency
department for insomnia, anxiety and
palpitations after attempting to wean himself off
of Phenibut. Patient endorses using
approximately 6g/day for 1 month for anxiolysis,
mood-stabilization and euphoria. Last dose was
10 hours prior to arrival. Patient has no past
medical or surgical history. Vitals were stable,
Wt 72 kg. Physical Exam unremarkable. Labs
unremarkable. Case reviewed with poison
control. Recommendation of self-taper of
Phenibut and Baclofen PRN for symptomatic
relief. Poison Control advised against
completely stopping Phenibut. Patient
discharged with 10 mg Baclofen TID PRN.

Chronic use of Phenibut clinically mimics presentations of other GABA agonist drugs of
abuse. Psychomotor agitation, anxiety, tremulousness, insomnia, hemodynamic instability,
hallucinations and seizures have been documented with severe Phenibut withdrawal. The
stoichiochemistry of Phenibut closely resembles Baclofen; both agonizing GABA-B
receptors. Due to similar stoichiochemistry, Baclofen lends itself useful for treating both
acute and chronic withdrawal of Phenibut. Baclofen is a GABA-B agonist, similar to Phenibut,
but does not have affinity for gamma-hydroxybutyrate (GHB) receptors. Baclofen’s lack of
affinity for GHB significantly reduces abuse potential, making Baclofen a safer withdrawal
agent when compared to other treatment modalities such as gabapentin, phenobarbital and
benzodiazpaines. According to Samokhvalov, Baclofen can be used for treatment of
phenibut dependence; 1 g of phenibut may be substituted w/ 8-10 mg of baclofen. Although,
medications such as phenobartital, Precedex and benzodiazapines have been shown to
successfully treat acute Phenibut withdrawal symptoms.
Despite its increasing popularity in the West as a new nootropic, Phenibut was developed in
the Soviet Union in St. Petersburg Russia during the 1960’s and has been available via
prescription in Russia for decades. Contributing to part of its lure in the West, Phenibut has
even been used to treat spaceflight asthenia in Cosmonauts. Phenibut is most often
purchased online in the US, where it is advertised as a nutritional supplement. Vendors often
advertise warnings against using more than 2000 mg daily, without directly addressing
withdrawal and toxicology potential. The combination of online accessibility, unscrupulous
marketing and addiction-potential lends Phenibut to be a destructive drug with withdrawals
physicians should be prepared to manage.

There was no funding related to this case report.
The authors declare that they have no
conflict of interest.

●

Discussion

Conclusions
Baclofen

● The emergence of easily accessible nootropic drugs poses an evolving
challenge for physicians. Physicians must remain informed of the
existence of new substances-of-abuse, their corresponding
mechanisms of action and their withdrawal managements. Phenibut
withdrawal may mimic the presentation of alcohol and benzodiazepine
withdrawal. Baclofen has shown potential in successfully treating
Phenibut withdrawal both outpatient and inpatient.
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